| Hans-Günter Meyer-Thompson | international
Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
Corace K, Suschinsky K, Wyman J, Leece P, Cragg S, Konefal S, Pana P, Barrass S, Porath A, Hutton B.
Int J Drug Policy. 2021 Dec 23;102:103573. doi: 10.1016/j.drugpo.2021.103573. Epub ahead of print. PMID: 35123246; PMCID: PMC8695187.